LinkedIn Icon
Returning October 2019
London, UK

 

 

 

 

2018 Speakers

Expand/Collapse

Samantha Parker
Chief Patient Access Officer
Lysogene

Conference Day Two

Wednesday, 24th October, 2018

13.15 | Presentation Details To Be Confirmed

Celine Bouquet
Preclinical Manager,
GenSight Biologics

Emily Culme-Seymour
Clinical Development Scientist, Rare Diseases
GSK

Conference Day One

Tuesday 23rd October, 2018

16.30 | Panel Discussion: Strategic Partnerships to Achieve Commercialisation: What are the Trends & What Does the Future Look Like?

Marcus Droege
Global Head, RWE & Registries
AveXis

Conference Day One

Tuesday 23rd October, 2018

09.30 | Panel Discussion: Evaluating Value-Based Pricing Models for Gene Therapy Products

Anne Douar
CDO
Vivet Therapeutics

Conference Day Two

Wednesday, 24th October, 2018

10.00 | Finding the Right Dose From Mice to Human: A Complex Equation

Alan Griffith
MSAT Manager
MeiraGTx

Conference Day Two

Wednesday, 24th October, 2018

15.45 | Chair’s Closing Remarks

11.30 | Panel Discussion: The Next Step – Pioneering Gene Therapies in More Common Diseases

09.00 | Scaling Manufacturing to Deal with the Demands of Commercial Gene Therapy Products

08.50 | Chair’s Opening Remarks

Matthew Hankinson
Associate Director, Analytical Development
Allergan

Conference Day Two

Wednesday, 24th October, 2018

09.30 | Developing Effective Process Characterisation & Analytical Tools

Sven Kili
VP, Head of Cell & Gene Therapy Development
GSK

Conference Day One

Tuesday 23rd October, 2018

17.00 | Chair’s Closing Remarks

11.15 | Establishing Effective Manufacturing & Regulatory Standards

08.20 | Chair’s Opening Remarks

Nerissa Kreher
CMO
Avrobio

Conference Day One

Tuesday 23rd October, 2018

11.30 | Incorporating Patient Input & Patient Reported Outcome Measures: A Fabry Clinical Trial Example

Aurelie Lambert
Manager, Regulatory Affairs EU
BioMarin

Conference Day Two

Wednesday, 24th October, 2018

14.45 | Tackling the Additional Complexities of GMO Applications to Save Crucial Development Time

Christine Le Bec
Head of CMC Analytics
Genethon

Pre Conference Workshop

Monday 22 October 2018

13.00 | Overcoming Analytical Challenges Encountered Throughout the Development of Gene Therapies

Robert Morgan
Executive Director, Regulatory Affairs
Nightstar Therapeutics

Conference Day Two

Wednesday, 24th October, 2018

13.45 | Engaging European Regulators Around Key Issues Throughout the Gene Therapy Development Process

Jan Nilsson
CEO
CombiGene

Conference Day Two

Wednesday, 24th October, 2018

11.30 | Panel Discussion: The Next Step – Pioneering Gene Therapies in More Common Diseases

Detlev Parow
Head, Pharmaceuticals Department
DAK-Gesundheit

Conference Day One

Tuesday 23rd October, 2018

09.30 | Panel Discussion: Evaluating Value-Based Pricing Models for Gene Therapy Products

09.00 | The Payer Perspective: Investigating how Gene Therapies Require a Fundamental Change in Healthcare Delivery

Steven Pearson
Founder & President
ICER

Conference Day One

Tuesday 23rd October, 2018

09.30 | Panel Discussion: Evaluating Value-Based Pricing Models for Gene Therapy Products

08.30 | How Will Value Frameworks and Budget Impact Analysis be Used to Evaluate Gene Therapies?

Isabelle Pengué Koyi
VP, Regulatory Affairs & Quality
GenSight Biologics

Conference Day Two

Wednesday, 24th October, 2018

15.15 | Managing Late-Stage Gene Therapy Development in Preparation for MA/BLA Applications

Markus Peters
CCO
Agilis Biotherapeutics

Conference Day One

Tuesday 23rd October, 2018

16.00 | Panel Discussion: Understanding Unique Challenges Involved in Developing Gene Therapies in a Biotech Environment

Lukas Fliedl
Process Manager
Shire

Conference Day Two

Wednesday, 24th October, 2018

11.00 | Navigating the Capacity Bottleneck – Contrasting In-House and External Manufacturing Options & Understanding the Shire Approach

Dominic Schmidt
Partner
Syncona

Conference Day One

Tuesday 23rd October, 2018

14.00 | Panel Discussion: Gaining Insights into How Investors View the Gene Therapy Space

Jeff Sevigny
CMO
Prevail Therapeutics

Conference Day Two

Wednesday, 24th October, 2018

11.30 | Panel Discussion: The Next Step – Pioneering Gene Therapies in More Common Diseases

Sander van Deventer
CSO, uniQure & Operating Partner
Forbion Capital Partners

Conference Day One

Tuesday 23rd October, 2018

14.00 | Panel Discussion: Gaining Insights into How Investors View the Gene Therapy Space

Samantha Vieira
Senior Director, Programme Management
Nightstar Therapeutics

Conference Day One

Tuesday 23rd October, 2018

12.00 | Developing & Commercializing Novel One-Time Treatments for Patients Suffering from Rare Inherited Retinal Diseases that would Otherwise Progress To Blindness – the Nightstar Approach

16.00 | Panel Discussion: Understanding Unique Challenges Involved in Developing Gene Therapies in a Biotech Environment

Hai Zhang
Director, Pharma M&A
Novartis

Conference Day One

Tuesday 23rd October, 2018

16.30 | Panel Discussion: Strategic Partnerships to Achieve Commercialisation: What are the Trends & What Does the Future Look Like?

Maureen Graham
Managing Director
Diamond Pharma Services

Conference Day One

Tuesday 23rd October, 2018

10.00 | Setting the Scene: Regulatory Insights & Nuances